James Mullen - Biogen Idec
Total Compensation: $20.3 million
Details: Even though he ended his tenure as Biogen Idec CEO in the middle of last year, James Mullen made out well, earning $20.3 million in 2010. While his salary was lower than previous years--a little under $794,000 versus $1.2 million in 2009--Mullen received a bonus of $653,400. He also received stock and option awards of more than $18.5 million--which, when taken together, were more than double than what they were in 2009, according to the company's proxy statement.
During his years at Biogen Mullen saw some turbulent times. He battled activist investor Carl Icahn and helped shepherd the approval and marketing of Tysabri--a drug that offered new hope to patients with multiple sclerosis. However, that drug, which still is a big seller, has been linked to a rare and often lethal brain infection. He also was forced to walk away from his $420 million bid to buy Facet Biotech, a cash-rich development partner that never saw enough money on the table to make an M&A deal worthwhile.
Mullen isn't out of the life science industry yet. Earlier this year, Toronto-based contract drug developer and manufacturer Patheon announced that Mullen had been named its new CEO.
Biogen Idec News:
FDA: Tysabri risks greatest during year 3
Biogen's Mullen earns $20M for a short year
Ex-Biogen CEO Mullen takes helm at Patheon
Biogen to cut 650 jobs in company revamp